MX2023012851A - Métodos de tratamiento y seguimiento de la enfermedad de parkinson. - Google Patents
Métodos de tratamiento y seguimiento de la enfermedad de parkinson.Info
- Publication number
- MX2023012851A MX2023012851A MX2023012851A MX2023012851A MX2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A MX 2023012851 A MX2023012851 A MX 2023012851A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- monitoring
- treatment
- parkinson
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000012544 monitoring process Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182207P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/026898 WO2022232487A1 (en) | 2021-04-30 | 2022-04-29 | Methods for treating and monitoring parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012851A true MX2023012851A (es) | 2024-03-19 |
Family
ID=83847331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012851A MX2023012851A (es) | 2021-04-30 | 2022-04-29 | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240207266A1 (https=) |
| EP (1) | EP4329763A4 (https=) |
| JP (1) | JP2024515885A (https=) |
| CN (1) | CN117769422A (https=) |
| AU (1) | AU2022267325A1 (https=) |
| CA (1) | CA3217230A1 (https=) |
| MX (1) | MX2023012851A (https=) |
| TW (1) | TW202308635A (https=) |
| WO (1) | WO2022232487A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025051214A1 (zh) * | 2023-09-07 | 2025-03-13 | 上海翊石医药科技有限公司 | 一种芳杂环类化合物及其制备方法 |
| CN121226329A (zh) * | 2024-06-28 | 2025-12-30 | 成都康弘药业集团股份有限公司 | 一种治疗或预防lrrk2介导的疾病的化合物 |
| CN119119035B (zh) * | 2024-08-30 | 2025-11-04 | 中山大学 | 一种ripk1激酶靶点抑制剂及其制备方法与应用 |
| CN118878521B (zh) * | 2024-09-26 | 2025-02-14 | 苏州美诺医药科技有限公司 | 一种lrrk2抑制剂的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102091895B1 (ko) * | 2012-05-03 | 2020-04-14 | 제넨테크, 인크. | 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체 |
| WO2014059052A1 (en) * | 2012-10-09 | 2014-04-17 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism |
| SMT202100699T1 (it) * | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
-
2022
- 2022-04-29 JP JP2023566921A patent/JP2024515885A/ja active Pending
- 2022-04-29 TW TW111116487A patent/TW202308635A/zh unknown
- 2022-04-29 US US18/288,734 patent/US20240207266A1/en active Pending
- 2022-04-29 WO PCT/US2022/026898 patent/WO2022232487A1/en not_active Ceased
- 2022-04-29 AU AU2022267325A patent/AU2022267325A1/en active Pending
- 2022-04-29 CN CN202280037732.0A patent/CN117769422A/zh active Pending
- 2022-04-29 EP EP22796791.6A patent/EP4329763A4/en active Pending
- 2022-04-29 MX MX2023012851A patent/MX2023012851A/es unknown
- 2022-04-29 CA CA3217230A patent/CA3217230A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329763A1 (en) | 2024-03-06 |
| CA3217230A1 (en) | 2022-11-03 |
| TW202308635A (zh) | 2023-03-01 |
| EP4329763A4 (en) | 2025-03-05 |
| AU2022267325A1 (en) | 2023-11-16 |
| WO2022232487A1 (en) | 2022-11-03 |
| US20240207266A1 (en) | 2024-06-27 |
| CN117769422A (zh) | 2024-03-26 |
| JP2024515885A (ja) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| NI201800124A (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| MX381069B (es) | Profármacos de carbidopa y l-dopa y métodos de uso. | |
| MX2020007060A (es) | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. | |
| MX2017014584A (es) | Inhibidores heterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| CR11723A (es) | Agente para tratar enfermedad | |
| UY32502A (es) | Agentes antihelmínticos y su utilización | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| MX2016011837A (es) | Composiciones de inhibidores de la dopa decarboxilasa. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| MX390084B (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| CO2022011388A2 (es) | Inhibidores heterocíclicos de pad4 | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| BR112017024727A2 (pt) | cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal | |
| ZA202000680B (en) | Obinutuzumab treatment of a dlbcl patient subgroup | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| MX2019002047A (es) | Metodos y composiciones para tratar infecciones fungicas cutaneas. | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| BR112017025189A2 (pt) | composição e usos da mesma |